Enhancing effects of chitosan and chitosan hydrochloride on intestinal absorption of berberine in rats

Drug Development and Industrial Pharmacy

Volumn 38, Issue 1, 2012, Pages 104-110

  Chen, Wei ^a   Fan, Dongjiao ^a   Meng, Lingkuo ^a   Miao, Yuqiang ^a   Yang, Shenshen ^a   Weng, Yan ^a   He, Haibing ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Absorption enhancer; Berberine chloride; Chitosan; Chitosan hydrochloride; Histopathological evaluation

Indexed keywords

BERBERINE; CHITOSAN; CHITOSAN HYDROCHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SOLUBILITY; HISTOPATHOLOGY; INTESTINE ABSORPTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; AREA UNDER CURVE; BERBERINE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; GASTROINTESTINAL TRACT; INTESTINAL ABSORPTION; MALE; RATS; RATS, WISTAR; SOLUBILITY; SOLUTIONS;

EID: 82455162793     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.592531     Document Type: Article

References (29)

1. Birdsall TC, Kelly GS. (1997). Berberine: Therapeutic potential of an alkaloid found in several medicinal plants. Alternative Medicine Review, 2:94-103.
2. Cheng ZF, Zhang YQ, Liu FC. (2009). Berberine against gastrointestinal peptides elevation and mucous secretion in hyperthyroid diarrheic rats. Regul Pept, 155:145-149.
3. Küpeli E, Kosar M, Yesilada E, Hüsnü K, Baser C. (2002). A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of Turkish Berberis species. Life Sci, 72:645-657.
4. Holy EW, Akhmedov A, Lüscher TF, Tanner FC. (2009). Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells. J Mol Cell Cardiol, 46:234-240.
5. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C et al. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med, 10:1344-1351.
6. Lau CW, Yao XQ, Chen ZY, Ko WH, Huang Y. (2001). Cardiovascular actions of berberine. Cardiovasc Drug Rev, 19:234-244.
7. Leng SH, Lu FE, Xu LJ. (2004). Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin, 25:496-502.
8. Piyanuch R, Sukhthankar M, Wandee G, Baek SJ. (2007). Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells. Cancer Lett, 258:230-240.
9. Qu QM, Zhang MF. (2002). The pharmacokinetics of berberine. Chin Acad Med Mag Organ 12:31-35.
10. Lv XY, Li J, Zhang M, Wang CM, Fan Z, Wang CY et al. (2010). Enhancement of sodium caprate on intestine absorption and antidiabetic action of berberine. Aaps Pharmscitech, 11:372-382.
11. Battu SK, Repka MA, Maddineni S, Chittiboyina AG, Avery MA, Majumdar S. (2010). Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. Aaps Pharmscitech, 11:1466-1475.
12. Cano-Cebrián MJ, Zornoza T, Granero L, Polache A. (2005). Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv, 2:9-22.
13. Aungst BJ. (2000). Intestinal permeation enhancers. J Pharm Sci, 89:429-442.
14. Ward PD, Tippin TK, Thakker DR. (2000). Enhancing paracellular permeability by modulating epithelial tight junctions. Pharm Sci Technol Today, 3:346-358.
15. Artursson P, Lindmark T, Davis SS, Illum L. (1994). Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res, 11:1358-1361.
16. Kato Y, Onishi H, Machida Y. (2003). Application of chitin and chitosan derivatives in the pharmaceutical field. Curr Pharm Biotechnol, 4:303-309.
17. Singla AK, Chawla M. (2001). Chitosan: some pharmaceutical and biological aspects-an update. J Pharm Pharmacol, 53:1047-1067.
18. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. (2001). Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci, 14:201-207.
19. Gupta PK, Hubbard M, Gurley B, Hendrickson HP. (2009). Validation of a liquid chromatography-tandem mass spectrometric assay for the quantitative determination of hydrastine and berberine in human serum. J Pharm Biomed Anal, 49:1021-1026.
20. Lu T, Liang Y, Song J, Xie L, Wang GJ, Liu XD. (2006). Simultaneous determination of berberine and palmatine in rat plasma by HPLC-ESI-MS after oral administration of traditional Chinese medicinal preparation Huang-Lian-Jie-Du decoction and the pharmacokinetic application of the method. J Pharm Biomed Anal, 40:1218-1224.
21. Misaki T, Sagara K, Ojima M, Kakizawa S, Oshima T, Yoshizawa H. (1982). Simultaneous determination of berberine, palmatine and coptisine in crude drugs and oriental pharmaceutical preparations by ion-pair high-performance liquid chromatography. Chem Pharm Bull, 30:354-357.
22. Pappenheimer JR. (1987). Physiological regulation of transepithelial impedance in the intestinal mucosa of rats and hamsters. J Membr Biol, 100:137-148.
23. Kotzé AF, Luessen HL, de Leeuw BJ, de Boer AG, Verhoef JC, Junginger HE. (1998). Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J Control Release, 51:35-46.
24. Schipper NG, Vårum KM, Artursson P. (1996). Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm Res, 13:1686-1692.
25. Luessen HL, de Leeuw BJ, Langemeÿer MW, de Boer AB, Verhoef JC, Junginger HE. (1996). Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res, 13:1668-1672.
26. Thanou M, Verhoef JC, Verheijden JH, Junginger HE. (2001). Intestinal absorption of octreotide using trimethyl chitosan chloride: studies in pigs. Pharm Res, 18:823-828.
27. Schipper NG, Vârum KM, Stenberg P, Ocklind G, Lennernäs H, Artursson P. (1999). Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. Eur J Pharm Sci, 8:335-343.
28. Schipper NG, Olsson S, Hoogstraate JA, deBoer AG, Vårum KM, Artursson P. (1997). Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res, 14:923-929.
29. Thanou M, Verhoef JC, Junginger HE. (2001). Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev, 52:117-126.